The 8-year overall survival rate was 78.9% with enzalutamide-leuprolide and 69.5% with leuprolide alone. Treatment with enzalutamide plus leuprolide reduces the risk of death by more than 40% in ...
XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...
The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with high-risk ...
Camcevi ETM contains 21mg of leuprolide and is administered every 3 months. The Food and Drug Administration (FDA) has approved Camcevi ETM ®, a long-acting formulation of leuprolide mesylate, for the ...
The National Institute for Health and Care Excellence (NICE) has recommended a new oral hormone therapy for advanced hormone-sensitive prostate cancer. In final draft guidance, NICE said that more ...
*Localized: T 1/2, NX or N0, and M0. ‡ Locally advanced: T3/4, NX or N0, and M0, or N1 and M0. ITT: Intention to treat; PSA: Prostate-specific antigen. Reproduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results